These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34130366)

  • 41. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 44. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
    Hirschl M; Kundi M
    Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis.
    Caldeira D; Nunes-Ferreira A; Rodrigues R; Vicente E; Pinto FJ; Ferreira JJ
    Arch Gerontol Geriatr; 2019; 81():209-214. PubMed ID: 30612074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry.
    Gorczyca I; Jelonek O; Uziębło-Życzkowska B; Chrapek M; Maciorowska M; Wójcik M; Błaszczyk R; Kapłon-Cieślicka A; Gawałko M; Budnik M; Tokarek T; Rajtar-Salwa R; Bil J; Wojewódzki M; Szpotowicz A; Bednarski J; Bakuła-Ostalska E; Tomaszuk-Kazberuk A; Szyszkowska A; Wełnicki M; Mamcarz A; Wożakowska-Kapłon B
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33167503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
    Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ
    Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
    Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
    Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
    Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
    J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies.
    Douros A; Durand M; Doyle CM; Yoon S; Reynier P; Filion KB
    Drug Saf; 2019 Oct; 42(10):1135-1148. PubMed ID: 31175610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
    Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.
    Fauchier L; Blin P; Sacher F; Dureau-Pournin C; Bernard MA; Lassalle R; Droz-Perroteau C; Dallongeville J; Moore N
    Europace; 2020 Feb; 22(2):205-215. PubMed ID: 31638652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
    Fernandez MM; Wang J; Ye X; Kwong WJ; Sherif B; Hogue S; Sherrill B
    SAGE Open Med; 2015; 3():2050312115613350. PubMed ID: 27092254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.
    Cohen AT; Hill NR; Luo X; Masseria C; Abariga SA; Ashaye AO
    Int J Cardiol; 2018 Oct; 269():174-181. PubMed ID: 30037626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.